Zyla Life Sciences (fka ZCOR)

[realfast95]

Earnings call transcript - note 1

http://seekingalpha.com/article/4053766-egalets-eglt-ceo-bob-radie-q4-2016-results-earnings-call-transcript?page=2

In addition, we are working to enhance OXAYDO's product profile. First, we're seeking to update the existing OXAYDO label with additional data characterizing the abuse-deterrent properties of the product. At PAINWeek last September, we presented data from a series of category one abuse-deterrent studies that showed under various conditions OXAYDO resisted syringeability. We submitted this data as part of a labeling supplement to the FDA. We expect FDA to take action of this filing by the end of this month. Given the fact that over 90% of all abusers have abused immediate release opioids this opportunity to strengthen the abuse section of the OXAYDO label could be an important development for this product.